COMPARISON OF DRUG DELAYS FOR NEW DRUGS APPROVED IN TÜRKİYE WITH INTERNATIONAL AUTHORITIES

Objective: The pharmaceutical industry is constantly increasing in importance due to the ever-increasing need for health services, rising living standards, increasing average life expectancy, and advances in health technology. The approval of a new drug in the world varies from country to country. There may be differences in the time delay in the release of an approved drug to the free market or the number of quantities in the total number of approved drugs between countries. Therefore, when the drugs are introduced to the market or allowed to be commercialized by the health authorities of the countries is of great importance.Material and Method: The research is a comparison of drug delays between the years between 2015-2024; the drugs approved by the Turkish Medicines and Medical Devices Agency (TITCK) and the health authorities of the US, Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Japan, Pharmaceuticals and Medical Devices Agency (PMDA), and the Canadian Drug Agency (CDA).Result and Discussion: The results obtained in the research show that there are absolute and relative drug delays in Türkiye. In addition, it is seen that the average number of days of drug delays in Türkiye is higher than FDA, EMA, CDA and PMDA. Türkiye experiences an average number of drug delays ranging from 298 to 1679 days. This also means that patients in Türkiye have a later access to drugs compared to other countries.